SITE015-0009

SITE015 (POL) › SITE015-0009

SITE015-0009

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2025-08-31

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 231); relationship: NOT RELATED

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-22 (study day 200); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 168); relationship: NOT RELATED

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-04 (study day 120); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.